CM Management’s Heron Therapeutics HRTX Stock Holding History

CM Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$427K	Hold	1,000,000	–	–	0.27%	68
2026 Q1	$800K	Buy	1,000,000 +250,000	+33%	+$290K	0.67%	54
2025 Q4	$975K	Hold	750,000	–	–	0.82%	43
2025 Q3	$945K	Buy	750,000 +150,000	+25%	+$238K	0.79%	49
2025 Q2	$1.24M	Hold	600,000	–	–	1.13%	31
2025 Q1	$1.32M	Sell	600,000 -100,000	-14%	-$194K	1.33%	32
2024 Q4	$1.07M	Buy	700,000 +200,000	+40%	+$324K	0.96%	40
2024 Q3	$995K	Buy	500,000 +200,000	+67%	+$478K	0.79%	45
2024 Q2	$1.05M	Hold	300,000	–	–	0.96%	39
2024 Q1	$831K	Sell	300,000 -25,000	-8%	-$62.8K	0.7%	47
2023 Q4	$553K	Sell	325,000 -125,000	-28%	-$138K	0.44%	53
2023 Q3	$464K	Sell	450,000 -50,000	-10%	-$71.2K	0.49%	49
2023 Q2	$580K	Buy	500,000 +150,000	+43%	+$268K	0.57%	50
2023 Q1	$529K	Buy	350,000 +100,000	+40%	+$250K	0.63%	44
2022 Q4	$625K	Sell	250,000 -25,000	-9%	-$80.5K	0.75%	46
2022 Q3	$1.16M	Buy	275,000 +75,000	+38%	+$293K	1.3%	28
2022 Q2	$558K	Hold	200,000	–	–	0.59%	52
2022 Q1	$1.14M	Buy	200,000 +150,000	+300%	+$1.1M	0.96%	35
2021 Q4	$457K	Sell	50,000 -10,000	-17%	-$102K	0.35%	76
2021 Q3	$641K	Buy	60,000 +10,000	+20%	+$122K	0.48%	66
2021 Q2	$776K	Hold	50,000	–	–	0.56%	63
2021 Q1	$811K	Buy	50,000 +35,000	+233%	+$624K	0.6%	65
2020 Q4	$317K	Buy	+15,000	New	+$261K	0.29%	70

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

CM Management's HRTX Position: Q2 2026 in Review

CM Management held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 1,000,000 shares worth $427K. The position accounts for 0.27% of the portfolio, ranked #68.

CM Management first reported a position in HRTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.32M in Q1 2025. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

CM Management held 1,000,000 shares of Heron Therapeutics worth $427K as of Q2 2026.
CM Management left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up 0.27% of CM Management's portfolio in Q2 2026, its #68 holding.
CM Management first reported a position in Heron Therapeutics in Q4 2020 and has held it in 23 quarters since.
CM Management's Heron Therapeutics position peaked at $1.32M in Q1 2025.
162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.